| Active substance | Garadacimab |
| Holder | CSL Behring |
| Status | closed |
| Indication | routine prevention of recurrent attacks of hereditary angioedema (HAE) in patients aged 12 years and older. |
| Public documents | Approbation |
| Information for the patient | |
| Informed consent - 12-17 year | |
| Informed consent - parents | |
| Informed consent - adult | |
| Last update | 26/03/2026 |